Updates from AACR25 by Amol Akhade
Apr 30, 2025, 08:50

Updates from AACR25 by Amol Akhade

Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared an updates from AACR25 on X:

“Exciting update from AACR25!
Combo of Botensilimab + Balstilimab in neoadjuvant setting:
  • pMMR tumors: 70% MPR
  • dMMR tumors: 80% MPR, 70% pCR
  • Low-grade irAEs and no surgical delays!
  • Organ preservation possible
  • High response even in ‘cold’ tumors like UPS, ER+BC, TNBC!
  • Promising step for neoadjuvant immunotherapy”Updates from AACR25 by Amol Akhade
BIG NEWS at AACR25
“Aumolertinib + Chemo for metastatic EGFR+ NSCLC!
  • Median PFS: 28.9 vs 18.9 months (HR 0.47)
  • Early OS trend: HR 0.44
  • Strong across all subgroups — gender, CNS mets, EGFR mutations
  • Especially powerful in young, smokers, Ex19del patients!
  • CNS control preserved!
Compared to Osimertinib+Chemo (FLAURA2):
Higher PFS
Better HRs across key groups
Could Aumolertinib + Chemo redefine EGFR NSCLC management? Or another Me Too combination?
Time will tell!
We need more global data and off course toxicity data”

Updates from AACR25 by Amol Akhade

More posts featuring AACR25